These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31647555)

  • 1. Understanding profit margins of medical providers from prescription drugs: evidence from Taiwan.
    Liu YM
    Int Health; 2020 Jul; 12(4):272-280. PubMed ID: 31647555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation and competition in the Taiwanese pharmaceutical market under national health insurance.
    Liu YM; Yang YH; Hsieh CR
    J Health Econ; 2012 May; 31(3):471-83. PubMed ID: 22525716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing of prescription drugs and its impact on physicians' choice behavior.
    Miao-Sheng C; Yu-Ti S
    Health Care Manag Sci; 2008 Sep; 11(3):288-95. PubMed ID: 18826006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases.
    Goupil B; Balusson F; Naudet F; Esvan M; Bastian B; Chapron A; Frouard P
    BMJ; 2019 Nov; 367():l6015. PubMed ID: 31690553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doctors who take company cash are more likely to prescribe brand name drugs, analysis finds.
    McCarthy M
    BMJ; 2016 Mar; 352():i1645. PubMed ID: 27000964
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessing the effects of drug price reduction policies on older people in Taiwan.
    Chu HL; Liu SZ; Romeis JC
    Health Serv Manage Res; 2011 Feb; 24(1):1-7. PubMed ID: 21285360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
    Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
    JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of generic entry in the regulated Taiwanese prescription drug market.
    Liu YM; Cheng JS
    Health Policy; 2012 Dec; 108(2-3):228-35. PubMed ID: 23020970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in PBM Business Practices in 2019: True Innovation or More of the Same?
    Motheral BR; Fairman KA
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1325-1333. PubMed ID: 32869706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.
    Wladysiuk M; Araszkiewicz A; Godman B; Szabert K; Barbui C; Haycox A
    Appl Health Econ Health Policy; 2011 Mar; 9(2):101-10. PubMed ID: 21271749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China.
    Zeng W
    BMC Health Serv Res; 2013 Oct; 13():390. PubMed ID: 24093493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
    Chen CL; Chen L; Yang WC
    BMC Public Health; 2008 Apr; 8():118. PubMed ID: 18405385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists.
    Morse E; Hanna J; Mehra S
    Otolaryngol Head Neck Surg; 2019 Oct; 161(4):605-612. PubMed ID: 31547772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice of generic versus brand-name antidepressants in a regulated prescription drug market: evidence from Taiwan.
    Liu YM; Ou HT; Yang YK
    J Ment Health Policy Econ; 2014 Dec; 17(4):163-72. PubMed ID: 25599280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of Market Exclusivity for Prescription Drugs in the United States.
    Kesselheim AS; Sinha MS; Avorn J
    JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes.
    Tsai YW; Wen YW; Huang WF; Kuo KN; Chen PF; Shih HW; Lee YC
    Eur J Health Econ; 2010 Jun; 11(3):279-90. PubMed ID: 19649666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.